1. Home
  2. OCUL
  3. OCUL News

Latest Ocular Therapeutix Inc. (OCUL) News on May 9, 2025

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
OCUL

Simply Wall St.

2 days ago

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations
OCUL

Simply Wall St.

3 days ago

Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
OCUL

Zacks

4 days ago

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

OCUL

MT Newswires

4 days ago

Ocular Therapeutix Q1 Net Loss Narrows, Revenue Falls

OCUL

Associated Press Finance

4 days ago

Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
OCUL

GlobeNewswire

4 days ago

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings
OCUL

GuruFocus.com

7 days ago

Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
OCUL

Zacks

10 days ago

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
OCUL

GlobeNewswire

10 days ago

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
OCUL

GlobeNewswire

11 days ago

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

a month ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OCUL

MT Newswires

a month ago

William Blair Initiates Ocular Therapeutix With Outperform Rating

Ocular Therapeutix™ to Participate in Two Investor Conferences in April
OCUL

GlobeNewswire

a month ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

OCUL

MT Newswires

2 months ago

RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target

Why Ocular Therapeutix Was Bumping Higher This Week
OCUL

Motley Fool

2 months ago

Why Ocular Therapeutix Was Bumping Higher This Week

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
OCUL

Benzinga

2 months ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

OCUL

MT Newswires

2 months ago

Needham Initiates Ocular Therapeutix at Buy With $15 Price Target

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...
OCUL

GuruFocus.com

2 months ago

Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

OCUL

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Ocular Therapeutix Inc Earnings Call

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
OCUL

Zacks

2 months ago

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

OCUL

MT Newswires

2 months ago

Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises

OCUL

Associated Press Finance

2 months ago

Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

Ocular Therapeutix Inc (OCUL) Q4 2024: Everything You Need To Know Ahead Of Earnings
OCUL

GuruFocus.com

2 months ago

Ocular Therapeutix Inc (OCUL) Q4 2024: Everything You Need To Know Ahead Of Earnings

Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?
OCUL

Zacks

2 months ago

Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?

Ocular Therapeutix™ to Present at Two Investor Conferences in March
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ to Present at Two Investor Conferences in March

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week
OCUL

Simply Wall St.

5 months ago

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix announces over 300 subjects randomized in SOL-1
OCUL

TipRanks

5 months ago

Ocular Therapeutix announces over 300 subjects randomized in SOL-1

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...
OCUL

GuruFocus.com

6 months ago

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
OCUL

Zacks

6 months ago

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

OCUL

Associated Press Finance

6 months ago

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL

MT Newswires

6 months ago

Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates
OCUL

Zacks

6 months ago

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings
OCUL

GuruFocus.com

6 months ago

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

OCUL

MT Newswires

7 months ago

Scotiabank Initiates Ocular Therapeutix at Sector Outperform

OCUL

MT Newswires

7 months ago

Ocular Therapeutix Speeds Up Timeline for Phase 3 Trial of Wet AMD Therapy; Shares Rise 7% Pre-Bell

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
OCUL

Zacks

7 months ago

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at October Ophthalmology Meetings
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength
OCUL

Zacks

7 months ago

Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

8 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at September Retina Meetings
OCUL

GlobeNewswire

8 months ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September
OCUL

GlobeNewswire

8 months ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
OCUL

Zacks

9 months ago

Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

With 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional owners
OCUL

Simply Wall St.

9 months ago

With 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional owners

OCUL

MT Newswires

9 months ago

Ocular Therapeutix Says FDA Agrees on Regulatory Path for Axpaxli in Wet AMD

OCUL

MT Newswires

9 months ago

Ocular Therapeutix's Shares Rise After Higher Q2 Revenue That Beat Forecast

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
OCUL

Zacks

9 months ago

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

OCUL

Associated Press Finance

9 months ago

Ocular Therapeutix: Q2 Earnings Snapshot

Ocular Therapeutix™ Reports Second Quarter 2024 Results
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

10 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing
OCUL

Simply Wall St.

10 months ago

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
OCUL

GlobeNewswire

10 months ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

10 months ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCUL

MT Newswires

a year ago

Ocular Therapeutix Shares Rise After TD Cowen Upgrades Rating, Increases Price Target

OCUL

MT Newswires

a year ago

TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7

OCUL

MT Newswires

a year ago

Sector Update: Health Care Stocks Decrease Late Afternoon

OCUL

MT Newswires

a year ago

Ocular Therapeutix Shares Rise Following Clinical Development Progress Report

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued
OCUL

Simply Wall St.

a year ago

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued

Ocular Therapeutix® to Host Investor Day on June 13, 2024
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCUL

MT Newswires

a year ago

Ocular Therapeutix Cutting 13% of Workforce

OCUL

MT Newswires

a year ago

Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
OCUL

GuruFocus.com

a year ago

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings

OCUL

Associated Press Finance

a year ago

Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix™ Reports First Quarter 2024 Results
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

2 Small-Cap Growth Stocks With Room to Run
OCUL

Motley Fool

a year ago

2 Small-Cap Growth Stocks With Room to Run

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
OCUL

Benzinga

a year ago

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
OCUL

Zacks

a year ago

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Share on Social Networks: